Adamis Pharmaceuticals

Its specialty pharmaceutical division currently has four products in its pipeline including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 (Dry Powder Inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. This division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. Adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. Within its biotechnology division, the Company has four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
14 (est)-6%
Adamis Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People at Adamis Pharmaceuticals

Dennis J. Carlo

Dennis J. Carlo

CEO
Robert O. Hopkins

Robert O. Hopkins

CFO

Adamis Pharmaceuticals Office Locations

Adamis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
300 11682 El Camino Real

Adamis Pharmaceuticals Data and Metrics

Adamis Pharmaceuticals Financial Metrics

Adamis Pharmaceuticals's revenue was reported to be $3 m in Q1, 2017
USD

Revenue (Q1, 2017)

3 m

Gross profit (Q1, 2017)

1.4 m

Gross profit margin (Q1, 2017), %

45%

EBIT (Q1, 2017)

(5.7 m)

Market capitalization (15-Aug-2017)

123.2 m

Cash (31-Mar-2017)

399.5 k
Adamis Pharmaceuticals's current market capitalization is $123.2 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

6.5 m

Cost of goods sold

4.9 m

Gross profit

1.6 m

Gross profit Margin, %

25%

R&D expense

9.7 m

General and administrative expense

17.1 m

Operating expense total

26.8 m

EBIT

(4.4 m)(13.9 m)(25.2 m)

EBIT margin, %

(389%)

Interest expense

(214.4 k)

Interest income

9.3 k

Income tax expense

4.6 m

Net Income

(8.2 m)(13.6 m)
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.9 m2.1 m3 m

Cost of goods sold

1.3 m1.8 m1.7 m

Gross profit

582.1 k254.5 k1.4 m

Gross profit Margin, %

30%12%45%

R&D expense

1.7 m597.5 k1.4 m1.3 m1.2 m3.4 m3.4 m1.5 m1.5 m

General and administrative expense

1 m1.3 m2.8 m2.3 m2.1 m2.6 m4.6 m5.3 m5.6 m

Operating expense total

2.8 m1.9 m4.1 m3.5 m3.3 m6 m8 m6.8 m7.1 m

EBIT

(2.8 m)(1.9 m)(4.1 m)(3.5 m)(3.3 m)(6 m)(7.4 m)(6.6 m)(5.7 m)

EBIT margin, %

(385%)(317%)(188%)

Interest expense

(225.9 k)(145.4 k)(225.9 k)(72.4 k)(70.2 k)(67.5 k)

Interest income

1671.3 k4 k
USDFY, 2014FY, 2015FY, 2016

Cash

5.4 m4.1 m4.1 m

Accounts Receivable

805.4 k

Inventories

14.5 k71 k942.1 k

Current Assets

4.2 m

Goodwill

7.6 m

Total Assets

15.1 m12.1 m37.8 m

Accounts Payable

671 k497.8 k2.2 m

Current Liabilities

8.6 m

Total Liabilities

12.5 m

Additional Paid-in Capital

58.3 m78.3 m113.7 m

Retained Earnings

(46.1 m)(69 m)(88.5 m)

Total Equity

9.3 m25.3 m

Financial Leverage

1.3 x1.5 x
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

2.1 m5.9 m11.2 m8.5 m6.3 m4.4 m417.1 k7.8 m399.5 k

Accounts Receivable

744.7 k595.6 k1.2 m

Inventories

1.2 m1.1 m914.2 k

Current Assets

2.2 m6 m11.3 m8.5 m6.4 m5 m2.6 m10.7 m

Goodwill

2.2 m2.2 m7.6 m

Total Assets

11.6 m15.1 m20 m16.9 m14.6 m12.7 m29.4 m36.7 m33.7 m

Accounts Payable

547.7 k750 k977.2 k498 k408.8 k1.5 m4.2 m1.7 m2.7 m

Current Liabilities

8.8 m

Additional Paid-in Capital

58.7 m63.9 m76.3 m77.1 m77.7 m84.1 m96.2 m112.6 m115.1 m

Retained Earnings

(49 m)(51.1 m)(58.6 m)(62.2 m)(65.4 m)(75.4 m)(81.1 m)(87.8 m)(94.2 m)

Total Equity

9.7 m12.8 m17.7 m14.8 m12.3 m8.7 m15 m24.8 m20.9 m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x1.2 x1.5 x2 x1.5 x1.6 x
USDFY, 2014FY, 2015FY, 2016

Depreciation and Amortization

888.4 k2.5 m

Inventories

14.5 k(165 k)1.9 k

Accounts Payable

671 k116 k(1.7 m)

Cash From Operating Activities

5.4 m306 k

Purchases of PP&E

(121.1 k)

Cash From Investing Activities

260.7 k

Short-term Borrowings

(38.7 k)

Cash From Financing Activities

4.8 m21.9 m

Interest Paid

89.4 k229.6 k

Income Taxes Paid

2.4 k19 k
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Accounts Receivable

744.7 k595.6 k1.2 m

Inventories

1.2 m914.2 k

Accounts Payable

547.7 k750 k977.2 k498 k408.8 k1.5 m4.2 m1.7 m2.7 m
USDY, 2017

Revenue/Employee

209.5 k

Financial Leverage

1.6 x

Adamis Pharmaceuticals Market Value History

Traffic Overview of Adamis Pharmaceuticals

Adamis Pharmaceuticals News and Updates

Mylan's generic version of the EpiPen is identical to the original — here’s why it can do that (MYL)

When Mylan Pharmaceuticals said Thursday that it would be giving a $300 "savings card" discount to patients buying a two-pack of EpiPens — a prescription with a retail price of around $600 — it didn't do much to fend off ire from politicians and the public. So, on Monday, th…

BRIEF-Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals

* Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals as of August 3, 2016 - SEC Filing Source - http://bit.ly/2aJYpKi Further company coverage:

BRIEF-Sabby Management LLC reports 7.8 pct passive stake in Adamis Pharmaceuticals

* Sabby Management, LLC reports 7.8 pct passive stake in Adamis Pharmaceuticals as of August 3, 2016 - SEC Filing Source - http://bit.ly/2aJYpKi Further company coverage:

Adamis Pharmaceuticals Company Life and Culture

You may also be interested in